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Abstract
Parasitic worms express host-like glycans to attenuate the immune response of human hosts. The
therapeutic potential of this immunomodulatory mechanism in controlling metabolic dysfunction
associated with chronic inflammation remains unexplored. We demonstrate here that
administration of Lacto-N-fucopentaose III (LNFPIII), a LewisX containing immunomodulatory
glycan found in human milk and on parasitic helminths, improves glucose tolerance and insulin
sensitivity in diet-induced obese mice. This effect is mediated partly through increased Il-10
production by LNFPIII activated macrophages and dendritic cells, which reduces white adipose
tissue inflammation and sensitizes the insulin response of adipocytes. Concurrently, LNFPIII
treatment up-regulates nuclear receptor Fxr-α (or Nr1h4) to suppress lipogenesis in the liver,
conferring protection against hepatosteatosis. At the signaling level, the extracellular signal-
regulated kinase (Erk)-Ap1 pathway appears to mediate the effects of LNFPIII on both
inflammatory and metabolic pathways. Our results suggest that LNFPIII may provide novel
therapeutic approaches to treat metabolic diseases.
Metabolic syndrome is a major medical and economic concern worldwide. Nutrient surplus
is causative to the obesity pandemic as well as increased metabolic burdens in mitochondria
and endoplasmic reticulum, leading to organelle dysfunction1. Chronic inflammation is a
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tcommon outcome to these metabolic stresses and a key contributor of pathologies associated
with metabolic diseases, such as insulin resistance, type 2 diabetes, atherosclerosis and
nonalcoholic fatty liver diseases. Although features of chronic “metabolic-related
inflammation” differ from those of acute inflammatory responses to exogenous insults,
studies have shown that several pathogen sensing mechanisms of innate immunity are
negative regulators of insulin sensitivity1. For example, pattern recognition receptors and
downstream effectors [e.g., toll-like receptor-4 (Tlr4), IκB kinase β (Ikk-β) and Ikk-ε, Tnf-
α and double-stranded RNA-dependent protein kinase] have been shown to be activated by
high fat feeding and to induce metabolic diseases2–6. In addition, activation of the
nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3
(Nlrp3) inflammasome, possibly in response to lipid metabolites (e.g., fatty acids and
ceramides)7,8, results in the cleavage of pro-caspase-1 (pro-Casp-1) and release of mature
Il-1β, which causes insulin resistance7,8.
Resident macrophages and lymphocytes in metabolic tissues, such as white adipose tissue
(WAT) and liver, are believed to play important roles in metabolic-related inflammation9–13.
Obesity triggers the infiltration of pro-inflammatory macrophages into WAT where they are
histologically presented as crown-like structures14,15. These so called “classically activated”
(or M1) macrophages are partly responsible for low-grade, chronic inflammation associated
with metabolic dysregulation1. In contrast, adipose resident macrophages (ATMs) from lean
individuals exhibit an “alternatively activated” (or M2) phenotype16, which functions to
repair damage inflicted by proinflammatory M1 signals17. Subsequent studies have
identified several sources of Th2 cytokines (e.g., Il-4 and Il-13) within WAT that mediate
alternative activation10,13,18. Depletion of Th2 cytokine producing cells or the downstream
mediators in macrophages leads to insulin resistance10,13,19. In contrast, increased Th2
cytokine production as seen in helminth infection, improves glucose homeostasis18. While it
remains unclear how Th2-biased, anti-inflammatory immune responses improve metabolic
homeostasis, over-expression of the anti-inflammatory cytokine Il-10 has been shown to
improve insulin sensitivity20.
The ability to drive Th2-type and anti-inflammatory responses during helminth infection has
been associated with decreased damage to host tissues, prolonging host survival21. During
infection with Schistosoma mansoni (S. mansoni), parasite eggs trapped in host tissues, such
as the liver, are the main stimuli for Th2 cytokine production in mice22. Injection of a saline
soluble homogenate of eggs (or soluble egg antigen, SEA) is sufficient to induce Th2-
biasing of the immune response23. Subsequently, it was shown that glycans and
glycoproteins found in SEA, such as the LewisX containing Lacto-N-fucopentaose III
(LNFPIII), LacdiNAc, fucosylated LacdiNac and omega-1 (a T2 RNase), are capable of
mediating the immunomodulatory activity24–27. Notably, LNFPIII is one of the major sugars
found in human milk post-partum and is thought to play a similar protective role in the
fetus28,29. These observations suggest that during co-evolution with human hosts, S.
mansoni parasites expressing immunomodulatory glycans were able to escape detection and
had a developmental advantage. In fact, macrophages treated with LNFPIII exhibit a Th2
cytokine-independent, M2-like phenotype, characterized by the expression of the M2
markers, arginase 1 (Arg1) and Ym130. LNFPIII and other helminth derived glycans induce
Il-10 production31, up-regulate T regulatory cell numbers32 and inhibit bacterial
lipopolysaccharide induced inflammatory responses31. The mechanisms through which
LNFPIII exerts these anti-inflammatory activities remain poorly characterized. It has been
shown that LNFPIII signals through several C-type lectin receptors33 and Tlr434, which lead
to activation of extracellular signal-regulated kinase (Erk). Although helminth infections
polarize the immune response towards the Th2 type, studies have shown that it reduces,
rather than exacerbates, the incidence of allergic responses, possibly because of the
regulatory activity of Il-1035.
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tIn the current study, we seek to further characterize the unique immunomodulatory activity
of LNFPIII and determine whether LNFPIII is effective in dampening chronic inflammation
and improving metabolic function in a diet induced model of type 2 diabetes. Our results
show LNFPIII or SEA treatment reduced inflammation and increased insulin sensitivity in
WAT in an Il-10-dependent manner. Further, LNFPIII directly regulates the lipogenic
program in hepatocytes and prevents obesity-induced hepatic steatosis through an
unexpected link to the nuclear receptor Fxr-α.
RESULTS
LNFPIII treatment improves insulin sensitivity
LNFPIII has been shown to induce M2-like macrophage activation, independent of Th2
cytokines30. We confirmed that LNFPIII treatment up-regulated Arg1, Ym1 and Mgl1
expression, albeit to a lesser extent than Il-4, in macrophages (Fig. 1a). In contrast, LNFPIII
was more effective than Il-4 in inducing Il-10 expression and release into macrophage
conditioned media (CM) (Fig. 1a,b and Supplementary Fig. 1a). This effect was blunted
when we treated macrophages with PD98059 to block the activity of Erk, which has been
implicated in mediating LNFPIII signal transduction (Fig. 1b)31,34,36. The Il-10 producing
activity of LNFPIII was also observed in dendritic cells (Supplementary Fig. 1b) and was
independent of Stat6 and Ppar-δ (known effectors of Th2 cytokines, Supplementary Fig. 1c).
Taken together, LNFPIII induces an anti-inflammatory state that increases Il-10 production.
To determine whether the immunomodulatory activity of LNFPIII might be beneficial for
treating metabolic diseases, we injected 8 week old male mice (C57BL/6) with vehicle or
LNFPIII (25 μg, twice a week) for 4–6 weeks following onset of high fat diet (HFD)
induced obesity and metabolic dysfunction. Consistent with the in vitro study, LNFPIII
treated mice had higher circulating Il-10 concentrations, while Il-4 remained unchanged
when compared to vehicle treated animals (Fig. 1c). When subjected to glucose tolerance
test (GTT), LNFPIII treated mice showed significantly higher glucose handling capability
versus the vehicle control group (Fig. 1d. Area under the curve, AUC: vehicle = 36,727.5 ±
1,769.13; LNFPIII = 29,244 ± 1,119.7, P = 0.0159). LNFPIII also improved insulin
sensitivity, compared to vehicle treatment, as demonstrated by reductions in fasting serum
insulin concentrations (vehicle: 1.54 ± 0.07; LNFPIII: 1.29 ± 0.06 ng ml−1, P < 0.05) and
improvement in insulin tolerance test (ITT, AUC: vehicle = 123.58 ± 4.79; LNFPIII = 98.23
± 3.30, P = 0.0357) and the homeostasis model of assessment-insulin resistance (HOMA-IR)
(Fig. 1e). Enhanced insulin signaling, based on insulin stimulated Ser473 Akt
phosphorylation, was observed in WAT but not in liver or muscle (Fig. 1f,g and data not
shown). We conducted parallel metabolic studies with SEA treatment, which led to higher
circulating Il-10 and Il-4 concentrations (Supplementary Fig. 1d). High fat fed mice treated
with SEA also displayed an improved insulin response determined by GTT, ITT, fasting
insulin levels and HOMA-IR (Supplementary Fig. 1e–g). LNFPIII or SEA treatment did not
affect body weight, food intake and circulating levels of lipids and adiponectin
(Supplementary Table 1). These studies demonstrate the potential of using glycans derived
from S. mansoni egg extract, including LNFPIII, to improve glucose homeostasis and
insulin sensitivity.
LNFPIII enhances WAT insulin signaling through Il-10
The interaction between resident macrophages and adipocytes plays an important role in
adipose tissue metabolic homeostasis10. WAT histological analyses demonstrated that mice
given LNFPIII had lower numbers of crown-like structures and reduced expression of F4/80
(a macrophage marker, Fig. 2a,b), compared to vehicle treated animals. In addition, Il-10
and M2 genes (Arg1 and Mgl1) were up-regulated, whereas Tnf-α and genes encoding the
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tinflammasome (Casp-1, Nlrp3, Il-18, and Il-1β) were down-regulated by LNFPIII treatment
(Fig. 2b). Consistent with the increased insulin sensitivity, expression of insulin receptor β
(InsR-β), insulin receptor substrate 2 (Irs2), C/ebp-α, glucose transporter 4 (Glut4) and
lipogenic genes were higher in WAT from LNFPIII treated mice, compared to vehicle
treated controls (Fig. 2c). C/ebp-α and Irs2 protein levels were also elevated (Fig. 2d). We
obtained similar results in SEA treated cohorts (Supplementary Fig. 2). Of note, SEA
induced Arg1 expression in WAT to a greater extent than LNFPIII, reflecting the fact that
SEA treatment increased serum Il-4 concentrations (Supplementary Fig. 1d). These data
support the notion that LNFPIII modulates WAT resident macrophage inflammation and
improves adipose tissue metabolic homeostasis.
Both in vitro and in vivo studies demonstrated that LNFPIII induced an anti-inflammatory
phenotype characterized by elevated Il-10 concentrations, which has been shown to improve
metabolic homeostasis20. To address whether the insulin sensitizing effect in WAT is a
direct action of LNFPIII or mediated by Il-10, we cultured 3T3-L1 adipocytes ± LNFPIII or
recombinant Il-10 (rIl-10). We observed that rIl-10, but not LNFPIII itself, improved insulin
responsiveness determined by insulin stimulated Akt phosphorylation, glucose uptake and
lipogenesis (Fig. 3a). CM from LNFPIII primed wild type (WT) macrophages, which
contained higher Il-10 concentrations (Fig. 1b), was able to reproduce the insulin sensitizing
activity in 3T3-L1 adipocytes, an effect abrogated in CM from LNFPIII primed Il-10−/−
macrophages (Fig. 3b). Furthermore, CM derived from LNFPIII primed WT, but not
Il-10−/−, macrophages induced the expression of InsR, Irs2 and C/ebp-α and suppressed
Il-1β and Tnf-α in 3T3-L1 adipocytes (Fig. 3c). Reconstitution of rIl-10 in CM from
Il-10−/− macrophages restored its ability to improve insulin stimulated glucose uptake and
modulate metabolic and inflammatory gene expression (Fig. 3b,c). In vivo, LNFPIII was
unable to improve insulin tolerance (Fig. 3d and Supplementary Table 1), enhance insulin
stimulated glucose uptake (Fig. 3e) and inhibit WAT inflammation (Supplementary Fig.
3a,b) in Il-10−/− mice. In addition, Il- 10−/− mice were more insulin resistant compared to wt
controls (Supplementary Fig. 3c). Reciprocally, rIl-10 injections (1μg, every other day for 3
doses) improved glucose tolerance and insulin sensitivity and recapitulated the WAT
phenotype observed in LNFPIII treated mice (Supplementary Fig 3d–h and Supplementary
Table 1). Taken together, the results suggest that Il-10 is required for LNFPIII mediated
improvement in WAT insulin signaling and systemic glucose homeostasis.
LNFPIII protects against diet-induced hepatic steatosis
In addition to improving WAT function, histological and triglyceride content analyses
showed a strong protective effect of LNFPIII against HFD-induced hepatic lipid
accumulation, compared to vehicle treated mice (Fig. 4a). Furthermore, overall liver
function, determined by circulating levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), was substantially improved (Fig. 4b). In line with reduced hepatic
steatosis, expression of lipogenic genes, including fatty acid synthase (Fas), acetyl-CoA
carboxylase1/2 (Acc1/2), stearoyl-CoA desaturase 1 (Scd1) and sterol regulatory element-
binding protein 1c (Srebp-1c), was lower in LNFPIII- versus vehicle-treated livers (Fig. 4c).
Srebp-1c is a master lipogenic transcription factor whose expression and transcriptional
activity are controlled by a network of nuclear receptor signaling pathways, notably, the
positive regulator Lxr-α (Nr1h3)37 and negative regulators Fxr-α (Nr1h4) and its target Shp
(Nr0b2)38. Fxr-α consists of two major 5′ regulatory regions, with the upstream and
downstream promoters driving the expression of Fxr-α1/α2 and Fxr-α3/α4 isoforms,
respectively39. The only difference between Fxr-α1/α2 (or Fxr-α3/α4) is a 4 amino acid
insertion in Fxr-α1 (or Fxr-α3). We found that expression of Fxr-α3/α4 isoforms as well as
several known Fxr target genes39, including Shp, organic anion-transporting polypeptides
(Oatp), phospholipid transfer protein (Pltp) and bile salt efflux pump (Bsep), were up-
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Lxr-α expression remained unchanged. We obtained similar effects with SEA treatment,
except that SEA up-regulated both Fxr-α1/α2 and Fxr-α3/α4 (Supplementary Fig. 4a–d).
LNFPIII or SEA treatment did not alter metabolic gene expression in muscle
(Supplementary Fig. 4e and data not shown). These results indicate that LNFPIII prevents
ectopic fat accumulation in the liver and regulates the expression of transcriptional factors
critical for de novo lipogenesis.
To assess the role of LNFPIII or LNFPIII primed macrophages in hepatic lipid homeostasis,
we conducted lipogenic assays in isolated primary hepatocytes. LNFPIII, but not CM from
LNFPIII treated macrophages, suppressed lipogenesis and increased fatty acid β-oxidation
compared to the vehicle treatment (Fig. 5a). LNFPIII also induced Fxr-α3/α4 and Shp as
well as suppressed Srebp-1c and Acc1 expression (Fig. 5b). Since LNFPIII did not affect β-
oxidation gene expression (Fig. 4c and 5b), the increased fat burning was likely secondary to
decreased fatty acid synthesis. These results suggest that unlike in WAT, the LNFPIII effect
in the liver was not mediated by Il-10. Consistent with this notion, rIl-10 treatment did not
affect hepatic de novo lipogenesis in vitro or in vivo (Supplementary Fig. 5a–c) and the
protective effect of LNFPIII was preserved in Il-10−/− liver (Supplementary Fig 5d,e).
LNFPIII suppresses hepatic de novo lipogenesis through Fxr
The up-regulation of the Fxr-α-dependent transcription program by LNFPIII suggested that
LNFPIII may induce Fxr-α to inhibit fat synthesis. In fact, in hepatocytes with Fxr-α gene
ablation or Erk inhibition by PD98059, LNFPIII was unable to inhibit de novo lipogenesis
and increase fat oxidation (Fig. 5c). Furthermore, the ability of LNFPIII to reduce hepatic
triglyceride accumulation, improve liver function and suppress lipogenic gene expression
was lost in Fxr-α−/− mice (Fig. 5d,e and Supplementary Fig. 5f), while the insulin
sensitizing activity of LNFPIII was unaffected (Supplementary Fig. 5g–i and Supplementary
Table 1). Together, the results suggest LNFPIII inhibits hepatic lipogenesis in a Fxr-α-
dependent manner.
We next sought to determine if Fxr-α is a molecular target of LNFPIII. As mentioned
earlier, both human and mouse Fxr-α contain two major promoters (Fig. 6a). The 5′
proximal regulatory sequences were highly conserved between mouse, rat and human FXR-
α genes (Supplementary Fig. 6a). We examined the activities of reporters driven by
upstream (promoter 1) or downstream (promoter 2) regulatory regions in HepG2 cells
(human hepatoma cells). In accordance with the regulation of Fxr-α in the liver or isolated
hepatocytes, LNFPIII activated human FXR-α promoter 2, while SEA induced the activity
of both promoters (Fig. 6a). In vivo, Fxr-α protein levels were higher in liver lysates from
LNFPIII versus vehicle treated mice (Fig 6a). Through serial deletion of promoter 2, we
defined a minimal LNFPIII responsive region (approximately 130 bp upstream of the
transcriptional start site) that contained consensus binding sites for C/EBP and AP1
(Supplementary Fig. 6a). Site directed mutagenesis experiments further identified two
overlapping AP1 sites (located between −57 and −47 bp) that were required for the
induction of FXR-α promoter 2 by LNFPIII (Fig. 6b and Supplemental Fig. 6b). Similarly,
inhibition of Erk activation, which is upstream of AP-1, by PD98059 abolished the LNFPIII
induced activity of FXR-α promoter 2. In concert, LNFPIII treatment increased levels of
phospho-Erk and total Erk in the liver (Fig. 6c) and hepatocytes (Fig. 6d). Similar results
were observed in SEA treated liver cells (Supplementary Fig. 6c–d). Collectively, these
findings suggest that LNFPIII regulates hepatic lipogenesis through the Erk-Ap1-Fxr-α axis.
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In this study, we demonstrate that LNPFIII (and SEA) alleviates the pathologies associated
with HFD-induced obesity. LNFPIII treatment shifts the immune profile to an anti-
inflammatory state and decreases macrophage infiltration in metabolic tissues of mice that
have already become obese. This effect is, in part, driven by Il-10, which inhibits
inflammation and enhances the insulin response in WAT. In the liver, LNFPIII up-regulates
bile acid sensing nuclear receptor Fxr-α and its downstream targets. Activated Fxr-α
signaling suppresses lipogenesis and protects against hepatic steatosis. Taken together, our
results demonstrate a therapeutic potential for LNFPIII in treating components of metabolic
syndrome through its ability to directly modulate both immune and metabolic pathways.
The hygiene hypothesis attributes the increased incidence of autoimmune diseases and
allergic responses in developed countries to reduced human contact with pathogens40. A
special emphasis has been on the interaction between parasitic worms and humans40,41; in
addition to the Th2 biasing immune phenotype, helminth infections induce the proliferation
of regulatory T cells and production of the anti-inflammatory cytokine Il-1042. Our data
show that LNFPIII treatment is sufficient to increase Il-10 production in macrophages and
dendritic cells. Regulatory T cells are likely another major source of Il-1042. These cells are
enriched in fat tissues from lean individuals and play a role in maintaining WAT function9.
Anti-inflammatory pathways are thought to improve metabolic homeostasis primarily
through attenuating the action of pro-inflammatory signaling. Over-expression of Il-10 in
the muscle was shown to improve systemic insulin resistance through suppression of
inflammation20. We find that in an Il-10 dependent manner, CM from LNFPIII treated WT
macrophages directly enhance insulin responses in adipocytes by up-regulation of InsR and
Irs2 and increase insulin mediated glucose uptake and lipogenesis. Acute rIl-10 injection in
high fat fed mice also improves glucose homeostasis but does not affect WAT macrophage
infiltration (data not shown), suggesting that the insulin sensitizing effect of Il-10 can be
separated from its anti-inflammatory activity. Several studies have identified IL-10
polymorphisms associated with insulin resistance/type 2 diabetes in humans43,44. Of note, a
previous study has demonstrated that deficiency in hematopoietic cell derived Il-10 in mice
through transplantation of Il-10−/− bone marrow does not affect high fat diet induced tissue
inflammation and insulin resistance45. However, Il-10 mRNA and protein levels are several-
fold higher in WAT and liver in these mice, compared to animals receiving WT bone
marrow. It is unclear whether the compensatory increase in Il-10 production is from non-
hematopoietic cells or from residual WT bone marrow-derived cells. The result seems to
suggest that increased Il-10 concentrations within metabolic tissues are sufficient to
maintain metabolic homeostasis.
While adipose tissue is known to produce adipokines, such as leptin, adiponectin and
resistin, to modulate systemic glucose and lipid metabolism, it is not a major tissue for
glucose uptake under physiological conditions. LNFPIII treatment does not affect the
expression of these adipokines in WAT (Supplementary Table 1 and data not shown). How
does increased WAT insulin sensitivity by LNFPIII lead to improvement in systemic
glucose homeostasis? It has been shown that GTT and ITT in muscle-specific insulin
receptor knockout (MIRKO) mice are indistinguishable from control animals, even though
insulin stimulated glucose uptake is substantially lower in muscle (the major site of glucose
disposal)46. Subsequent studies attribute the normo-glycemic phenotype of MIRKO mice to
a three-fold higher glucose deposition to WAT compared to control mice47, suggesting that,
at least in mice, increased glucose uptake by adipocytes is able to sustain glucose
homeostasis. Consistent with this notion, over-expression of the glucose transporter Glut4 in
adipose tissues improves glucose tolerance48. Recently, increased glucose flux in adipocytes
has been shown to up-regulate fatty acid synthesis through a novel isoform of carbohydrate-
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tresponsive-element-binding protein, Chrebp-β49. In addition, the expression of adipose
ChREBP-β and lipogenic genes positively correlates with insulin sensitivity in humans49.
Our data demonstrate that LNFPIII treatment increases WAT glucose uptake and lipogenic
gene expression. Chrebp-β is also induced (data not shown). While the mechanism through
which fat synthesis in adipose tissues contributes to whole body homeostasis is not
completely understood, a lipogenic product of adipocytes has been linked to improved
systemic metabolism50. The beneficial effect of LNFPIII could also be mediated by central
regulation, in which reduced inflammation may lead to improved central insulin sensitivity
that is known to regulate hepatic glucose production51. However, LNFPIII does not seem to
affect gluconeogenesis based on pyruvate tolerance tests and the expression of
gluconeogenic genes in the liver (data not shown).
After entering the body, S. mansoni settles in the hepatic portal system where male and
female worms mate and produce eggs22. Egg deposition in the liver is critical for induction
of a systemic Th2 response22. It is therefore not surprising that the liver is also a target of
LNFPIII. At first glance, it seems unexpected that LNFPIII directly controls Fxr-α signaling
to regulate hepatic lipid metabolism. Fxr-α senses endogenous bile acids and controls bile
acid homeostasis by inhibiting production while increasing the recycling of bile acids in the
enterohepatic system52. Fxr-α activation also suppresses lipogenesis through Shp-mediated
inhibition of Srebp-1c in the liver38. Interestingly, S. mansoni is incapable of de novo
synthesis of fatty acids and sterols but is able to synthesize complex lipids from precursors
acquired from the host53. In addition, it has been shown that bile acids increase the number
of deposited parasite eggs54. Therefore, the induction of Fxr-α by LNFPIII could be the
host’s response to limit fatty acids and bile acids available to the worm. In contrast, bile
acids facilitate lipid absorption in the intestine. Increased bile flow via Fxr-α may help
schistosomes to extract lipids from the digestive system of the host. Additionally, the
induction of Fxr-α could serve as an anti-inflammatory mechanism in the liver as Fxr-α is
known to trans-repress Nf-κb activity55.
The signal transduction pathway of LNFPIII has not been fully characterized. In dendritic
cells, LNFPIII is recognized by multiple C-type lectin receptors, including DC-SIGN, Mgl1
and mannose receptor. In addition, Erk is proposed to be a downstream effector of
LNFPIII31,56. Erk-Ap1 has been shown to regulate Il-10 expression36. Indeed, the ability of
LNFPIII to induce Il-10 production in the macrophage was blocked by Erk inhibition. We
find that primary hepatocytes also express CLRs, such as DC-SIGN (data not shown) and
LNFPIII is able to activate Erk in the liver, which mediates Fxr-α transcriptional regulation
and the subsequent suppression of lipogenesis. The gene products of the two promoters
(Fxr-α1/α2 versus Fxr-α3/α4) differ by several amino acids located at the N-terminus.
Functional differences between isoforms have not been reported39. Our data suggests that
the induction of Fxr-α3/α4 by LNFPIII is sufficient to suppress lipogenesis. While LNFPIII
only activates the downstream Fxr-α promoter, SEA induces the activities of both
promoters. This is not unexpected, since SEA is known to contain multiple bioactive glycans
that could signal through different pathways56. Together, our data show that helminths may
utilize the Erk-Ap1 signaling pathway to modulate host metabolism and immune responses
(Fig. 6e). Our study suggests that the M2-like, anti-inflammatory activity of LNFPIII, which
is likely the product of helminth’s survival strategy, may be used to treat metabolic
disorders, such as insulin resistance and nonalcoholic fatty liver diseases.
ONLINE METHODS
Animal experiments
We placed male C57BL/6J mice at 8–10 weeks of age (obtained from The Jackson
Laboratory) on a high-fat, high-carbohydrate diet (F3282, Bio-Serv) for the duration of the
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texperiments. Six weeks after high fat feeding, we injected mice (i.p.) twice per week with 25
μg of dextran (40 kDa, vehicle) or LNFPIII conjugated to dextran (~8–10 LNFPIII per
dextran). Experiments were reproduced in three independent mouse cohorts (n = 5–7 per
treatment). We conducted similar metabolic experiments in three additional cohorts (n = 4–6
per treatment), which were given 0.9% NaCl (vehicle) or SEA dissolved in 0.9% NaCl (25
μg, twice a week). LNFPIII and SEA were prepared as described30,57. Metabolic studies
started 4 weeks after LNFPIII or SEA treatment and were conducted after 6 h fasting. We
sacrificed animals at the 6th week of treatment for serum and tissue collection. For rIl-10
experiments, mice were treated with PBS (vehicle) or rIl-10 (Peprotech; 1μg, i.p. every
other day for a total of 3 doses) after 4 weeks of high fat diet. Body weight and food intake
were monitored weekly. We performed GTT by injecting 1 g glucose per kg body weight
into mouse peritoneum and measured blood glucose before and after injection at the time
points indicated using a OneTouch glucose monitoring system (LifeScan). ITT was
conducted similarly by injecting 1 U per kg body weight of insulin. In vivo insulin signaling
was determined by injecting 5 U per kg body weight of insulin through the portal vein. We
collected pieces of liver, epididymal fat and muscle before and 10 minutes after insulin
injection and rapidly stored tissues in liquid nitrogen. Additional adipose tissue slices were
immediately incubated with 2-[H3]deoxy-D-glucose to determine insulin stimulated glucose
uptake ex vivo. To estimate crown like structures, we divided one piece of epididymal fat
pad into three sections and embedded them in a single paraffin block. We collected
sequential sagittal sections every 20 μm for H&E staining. HOMA-IR was calculated as
described58. Serum and tissue lipids, ALT and AST were measured using commercial kits as
described previously59. We determined concentrations of p-Akt, t-Akt, insulin, Il-10 and Il-4
using ELISA-based plates from Meso Scale Discovery and Peprotech. The Dana-Farber/
Harvard Cancer Center Research Pathology Core provided all histological services and
preliminary assessments by a pathologist. We obtained Il-10−/− and Fxr-α−/− mice (male, n
= 6 per genotype per treatment, C57BL/6J background) from the Jackson Laboratory.
Metabolic studies and treatments in these animals were similar to those in wt C57BL/6 mice.
The Harvard Medical Area Standing Committee on Animals approved all the animal
protocols.
Immunoblotting experiments
We performed Western blot analyses using antibodies to detect the following proteins: p-
Akt (Cell Signaling # 9271, 1:1000); t-Akt (Cell signaling # 9272, 1:1000); Fxr-α (R&D
systems, # PP-A9033A-00, Clone A9033A, 1:500 and Santa Cruz Biotechnology # sc-1204,
1:500); Irs-2 (Santa Cruz # sc-8299, 1:500); C/ebp-α (Santa Cruz # sc-61, 1:500); actin
(Cell Signaling # 4970, Clone 13E5, 1:1000); tubulin (Cell Signaling # 2128, Clone 9F3,
1:1000). p-Erk (Cell signaling # 9101, 1:1000); t-Erk (Cell signaling # 4695, 1:1000).
Primary cells, adipocyte differentiation and functional assays
We differentiated bone marrow-derived macrophages in L929 conditioned media as
previously described10. Dendritic cells were differentiated in the presence of M-CSF (3 ng
mL−1) and Il-4 (5 ng mL−1). For CM, we treated cells with dextran (control) or LNFPIII (20
μg ml−1) overnight. Following treatment, cells were washed and cultured in DMEM alone.
We collected media 8 hours later and added 10% FBS, which constituted the CM. For M2
skewing experiments, we treated macrophages with dextran, LNFPIII (20 μg ml−1) or Il-4
(20 ng ml−1) overnight. Where indicated, cells were pretreated for 1 hour with PD98059 (10
μM, Cell Signaling) prior to treatments. PD98059 is an MEK1 (also called MAPKK or Erk
kinase) inhibitor used to block Erk activation. We differentiated 3T3L1 cells in a cocktail
containing insulin, isobutylmethylxanthine, and dexamethasone. For differentiation
experiments, 3T3-L1 cells were given various treatments indicated together with the
differentiation cocktail. At day 2, the cocktail was removed and differentiation continued in
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differentiation. Cellular lipids were extracted with a 2:1 (v/v) chloroform:methanol solution.
For insulin signaling experiments, we treated fully differentiated 3T3-L1 adipocytes (at day
6) with the indicated treatments for 48 hr without insulin. Cells were washed, serum starved
for 2 h and stimulated with insulin (100 nM) for 60 min. We conducted glucose uptake using
2-[H3]deoxy-D-glucose with a 20 min insulin pre-stimulation. Cellular radioactivity was
determined and normalized to protein content. Primary hepatocytes were isolated as
previously described59,60. Hepatocytes were allowed to attach overnight in William’s E, 5%
FBS, followed by treatments for 24 h. For de novo lipogenesis, we labeled cells with 14C-
acetate and extracted lipids with a 2:1 (v/v) chloroform:methanol mixture 6 h later. β-
oxidation was conducted as described previously60. For LNFPIII signaling, attached
hepatocytes were pretreated with Erk inhibitor where indicated for 1 hr followed by a 30
min incubation with dextran or LNFPIII.
Expression analyses
For gene expression analyses, we determined relative expression levels using SYBR green-
based real-time quantitative PCR (q-PCR) reactions. We used 36B4 levels for normalization.
For western blot analyses, we prepared tissue and cell lysates in the presence of protease and
phosphatase inhibitors. The four Fxr-α (Nr1h4) isoforms were based on previous reports,
which were originally designated as Fxr-α1/α2 and Fxr-β1/β2. The latter were renamed as
Fxr-α3/α4 to avoid confusion with the rodent Fxr-β (Nr1h5)39. For reporter assays, we
cloned the upstream promoter 1 and downstream promoter 2 regions of human FXR-α gene
into the pGL3-basic luciferase reporter vector and conducted transient transfection in HepG2
cells in a 96-well format. We used a β-galactosidase reporter construct for normalization.
Statistical analyses
Statistical analyses comparing two parameters (between treatments or genotypes) in cell-
based work were conducted using the two-tailed Student’s t test. Two parameters analyses
for samples from in vivo studies (non-gaussian distribution) were determined using the
Mann-Whitney test (Figs. 1c, 1g, 2a–d, 3e, 4a–c, 5d–e, 6c, Supplementary Figs. 1d, 1g, 2b–
c, 3a, 3b, 3f–h, 4a–d, 5d–e, 5i and Supplementary Table 1). Statistics for multi-parameter
analyses was determined by One-Way ANOVA followed by Bonferroni posthoc tests (Figs.
1a, 3a–c, 5a, 5c, 6a, 6d and Supplementary Figs. 1a, 5a, 6c–d). Two-way ANOVA was used
to determine statistical significance for GTT and ITT (Figs. 1d–e, 3d and Supplementary
Figs. 1e–f, 3c–e, 5f–g). Values are presented as mean ± SEM. For in vitro assays, the mean
and SEM were determined from 3–4 biological replicates for one representative experiment.
Experiments were repeated at least three times. P < 0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
LNFPIII increases Il-10 production and improves insulin sensitivity. (a) Real-time q-PCR
examining the expression of M2 (alternative activation) genes in bone marrow derived
macrophages treated with Il-4 (20 ng ml−1) or LNFPIII (20 μg ml−1) for 24 hr. (b) Il-10
concentrations in conditioned medium from LNFPIII or vehicle treated macrophages
determined by ELISA. PD98059 (10 μM): Erk inhibitor. (c) Serum Il-10 and Il-4
concentrations in vehicle or LNFPIII treated mice (n = 5–7 per treatment) (d and e) Glucose
tolerance test (GTT, d) and insulin tolerance test (ITT, e) in vehicle and LNFPIII treated
mice. Inset in (e): homeostasis model of assessment-insulin resistance (HOMA-IR). (f)
Western blot analyses to examine insulin stimulated Akt phosphorylation in WAT from
vehicle and LNFPIII treated mice (from four individual mice per treatment). p-Akt:
phospho-Akt; t-Akt: total Akt. (g) The relative level of p-Akt to t-Akt in WAT ±insulin
injection quantified by densitometry based on Western signals in (f) or by ELISA-based
assays. Values are expressed as means ± SEM. For in vitro assays, the mean and SEM were
determined from 3–4 biological replicates for a representative experiment. Experiments
Bhargava et al. Page 13
Nat Med. Author manuscript; available in PMC 2013 May 01.
$
w
a
t
e
r
m
a
r
k
-
t
e
x
t
$
w
a
t
e
r
m
a
r
k
-
t
e
x
t
$
w
a
t
e
r
m
a
r
k
-
t
e
x
twere repeated 3 times. In vivo studies were reproduced in three mouse cohorts (n = 5–7 per
treatment). Insulin signaling was examined in two of the three cohorts. *P < 0.05 (LNFPIII
or Il-4 versus vehicle control).
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Reduced inflammation and enhanced insulin signaling in WAT of LNFPIII treated mice. (a)
Left panel: WAT histology showing crown-like structures (CLS, indicated with arrows).
Scale bar: left images = 400 μm; right images = 100 μm. Right panel: CLSs quantified in 90
fields from 30 sections (3 fields per section) for each individual animal (n = 4 per group). Y-
axis: % fields that contains certain percentage of CLSs; X-axis: % CLS-containing
adipocytes in a given field; n.d: not detected. (b) Real-time q-PCR analyses of M1 and M2
gene expression in WAT of vehicle- and LNFPIII-treated mice (n = 5 per treatment). (c)
Metabolic gene expression in WAT determined by real-time q-PCR. (d) Western blotting
showing C/ebp-α and Irs2 protein levels in WAT. Bottom panel: relative C/ebp-α and Irs2
levels normalized to tubulin. Values are expressed as means ±SEM. Metabolic studies were
reproduced in three mouse cohorts (n = 5–7 per treatment). Crown-like structures and
expression analyses were examined in one and three of the three cohorts, respectively. *P <
0.05 (LNFPIII versus vehicle).
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LNFPIII primed macrophage conditioned medium improves insulin sensitivity in 3T3L1
adipocytes in an Il-10 dependent manner. (a) Top panel: Western blotting showing protein
levels of total Akt (t-Akt) and insulin stimulated Akt phosphorylation (p-Akt) in 3T3-L1
adipocytes treated with vehicle, LNFPIII or rIl-10 (representative samples from three
experiments each with three biological replicates). Bottom left panel: insulin stimulated
glucose uptake determined using radioactive 2-[H3]deoxy-D-glucose. Bottom right panel:
cellular triglyceride contents measured at day 6 of 3T3-L1 adipocyte differentiation. Vehicle
controls for LNFPIII (20 μg ml−1) and Il-10 (10 ng ml−1) were dextran and PBS,
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trespectively. (b) Top panel: Western blotting showing protein levels of t-Akt and insulin
stimulated p-Akt in adipocytes treated with control and conditioned medium (CM) from
LNFPIII primed wt and Il-10−/− macrophages. Bottom panel: insulin stimulated glucose
uptake in adipocytes. (c) Gene expression in 3T3-L1 adipocytes determined by real-time q-
PCR. (d) Insulin tolerance test in vehicle and LNFPIII treated Il-10−/− mice (n = 6 per
treatment per genotype). AUC: area under the curve of ITT. (e) Ex vivo glucose uptake
assay performed in adipose tissue slices collected before and after portal vein injection of 5
U kg−1 insulin. Values are expressed as means ±SEM. For in vitro assays, the mean and
SEM were determined from 3–4 biological replicates for a representative experiment.
Experiments were repeated three times. Studies in Il-10−/− and control mice were conducted
in one cohort (n = 6). *P < 0.05 (treatment versus control).
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tFigure 4.
LNFPIII protects against high fat diet induced hepatic steatosis. (a) Liver histology and
triglyceride content analyses to determine hepatic fat accumulation in vehicle and LNFPIII
treated mice. Scale bar = 100 μm. (b) Circulating AST and ALT concentrations to assess
liver function. (c) Gene expression analyses in livers from vehicle or LNFPIII treated mice
(n = 5) by real-time q-PCR. Values are expressed as means ±SEM. Metabolic studies were
reproduced in three mouse cohorts (n = 5–7 per treatment). Histology was examined in one
and lipid and expression analyses were examined in three of the three cohorts. *P < 0.05
(LNFPIII versus vehicle control).
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LNFPIII suppresses lipid synthesis through Fxr-α. (a) De novo lipogenesis (left panel) and
fatty acid β-oxidation (right panel) assays in primary hepatocytes treated with vehicle,
LNFPIII (20 μg ml−1) or CM from LNFPIII primed wt macrophages. (b) Gene expression in
hepatocytes treated with vehicle or LNFPIII determined by real-time q-PCR. (c) Lipogenic
(left panel) and β-oxidation (right panel) assays in hepatocytes isolated from wild type (WT)
or Fxr-α−/− mice ±LNFPIII ±PD98059. (d and e) Hepatic triglyceride content and serum
AST and ALT concentrations in WT and Fxr-α−/− mice ±LNFPIII treatment (n = 6). Values
are expressed as means ±SEM. For in vitro assays, the mean and SEM were determined
from 3–4 biological replicates for a representative experiment. Experiments were repeated 3
times. Studies for Fxr-α−/− and control mice were conducted in one cohort (n = 6 per
treatment per genotype). *P < 0.05 (LNFPIII versus vehicle control).
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Induction of Fxr-α activity by LNFPIII is mediated by Erk-Ap1 signaling. (a) Top panel:
genomic structure showing alternative promoter usage by human FXR-α1/α2 (promoter 1)
and FXR-α3/α4 (promoter 2). Bottom left: Relative activities (RLU) of luciferase reporters
driven by human FXR-αpromoter 1 (~2 kb) or human FXR-αpromoter 2 (~0.13 kb) in
HepG2 cells ±LNFPIII (20 μg ml−1) or SEA (2 μg ml−1). Bottom right: Western blotting
showing Fxr-α protein levels in livers from vehicle or LNFPIII treated mice. (b) Top panel:
diagram demonstrating FXR-α promoter 2 (p2–0.13kb) or mutant (p2–0.13kb–M) reporter
constructs. The two overlapping AP1 binding sites and the mutation are shown. Bottom
panel: Relative luciferase activities of p2–0.13kb and p2–0.13kb–M ± LNFPIII ± PD98059
(c) Erk phosphorylation (p-Erk) in livers of vehicle and LNFPIII treated mice. Bottom
panel: Quantification of the Western signal. (d) Western blot analyses showing Erk
phosphorylation in hepatocytes ± LNFPIII±PD98059 (representative samples from three
experiments each with three biological replicates). Bottom panel: Quantification of the
Western signal. Values are expressed as means ± SEM. For in vitro assays, the mean and
SEM were determined from 3–4 biological replicates from one of three repeats. Hepatic p-
Erk was determined from one of three metabolic study cohorts (n = 5, showing 3
representative samples). *P < 0.05 (LNFPIII or SEA versus vehicle control). (e) Model for
direct and indirect regulation of metabolic pathways by LNFPIII. DC: dendritic cells.
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